title: Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
abstract: Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.
authors: Department of Hematology, Japanese Red Cross Medical Center, Hiroo 4-1-22 Shibuya-ku, Tokyo, 1508935, Japan, ken-suzuki@mtb.biglobe.ne.jp.
authors: Kenshi
authors: K
authors: Suzuki
authors: Michinori
authors: M
authors: Ogura
authors: Yu
authors: Y
authors: Abe
authors: Tatsuya
authors: T
authors: Suzuki
authors: Kensei
authors: K
authors: Tobinai
authors: Kiyoshi
authors: K
authors: Ando
authors: Masafumi
authors: M
authors: Taniwaki
authors: Dai
authors: D
authors: Maruyama
authors: Minoru
authors: M
authors: Kojima
authors: Junya
authors: J
authors: Kuroda
authors: Meguru
authors: M
authors: Achira
authors: Koho
authors: K
authors: Iizuka
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology*; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000276:immunology; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001897:Boronic Acids; D015850:Interleukin-6; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; C504234:siltuximab
references: Leukemia. 2009 Nov;23(11):1964-79
references: 19741722
references: Cell Immunol. 1995 May;162(2):248-55
references: 7743552
references: N Engl J Med. 2004 Oct 28;351(18):1860-73
references: 15509819
references: Clin Cancer Res. 2014 Apr 15;20(8):2192-204
references: 24563479
references: Br J Haematol. 2009 May;145(4):481-90
references: 19344406
references: Clin Cancer Res. 2007 Nov 1;13(21):6469-78
references: 17975159
references: Br J Haematol. 2013 May;161(3):357-66
references: 23432640
references: Blood. 2000 Nov 1;96(9):3175-80
references: 11050000
references: Blood. 1994 Nov 1;84(9):3063-70
references: 7949178
references: Clin Cancer Res. 2013 Jul 1;19(13):3659-70
references: 23659971
references: Cell Death Differ. 2009 Mar;16(3):368-77
references: 18846109
references: Blood. 1995 Feb 15;85(4):863-72
references: 7849308
references: J Biol Chem. 2000 Sep 8;275(36):27845-50
references: 10880513
references: Leukemia. 2006 Sep;20(9):1467-73
references: 16855634
references: Nature. 1988 Mar 3;332(6159):83-5
references: 3258060
references: Clin Cancer Res. 2009 Dec 1;15(23):7144-52
references: 19934301
references: Br J Haematol. 1998 Sep;102(5):1115-23
references: 9753033
references: Leuk Res. 2013 Oct;37(10):1322-8
references: 23871159
references: Oncologist. 2011;16(4):497-511
references: 21441298
references: Nat Rev Cancer. 2007 Aug;7(8):585-98
references: 17646864
references: Leukemia. 2009 Mar;23(3):449-56
references: 19005483
references: J Clin Oncol. 2010 Aug 10;28(23):3701-8
references: 20625121